Assessment of Individual Donor Nucleic Acid Test (ID-NAT) For Human Immunodeficiency Virus 1 & 2 and Hepatitis B & C Virus in Blood Donors
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 11, Pages 8908-8913
AbstractBackground:The present study was undertaken for assessing Individual Donor Nucleic Acid Test
(ID-NAT) For Human Immunodeficiency Virus 1 & 2 and Hepatitis B & C Virus in Blood Donors.
Materials & methods:The present study was undertaken for assessing Individual Donor Nucleic
Acid Test (ID-NAT) For Human Immunodeficiency Virus 1 & 2 and Hepatitis B & C Virus in
Blood Donors. All the blood samples of blood donors were screened by ID NAT and ELISA for
HIV1&2, HCV and HBV. Samples from donated blood units would be screened by ID NAT
byProcleix® Ultriopluselite® Assay (Panther® Grifols Diagnostic Solutions Inc. Emeryville,
USA)and by Enzyme-Linked Immunosorbent Assay (ELISA). Results of ELISA and NAT tests
were compiled every day. Units which were reactive by any tests were segregated and kept in
quarantine area, and sent for disposal using biohazard labels. We assessed the seroprevalence of
HIV1&2, HCV and HBV by ID NAT testing among the entire voluntary and replacement donors
between 18-65 years of age. All the results were recorded in Microsoft excel sheet and were
analysed by SPSS software.
Results:A total number of 26474 blood donors were screened for HIV-1 & 2, HCV & HBV over
duration of one year. Out of them, 13998 were voluntary donors and 12476 were replacement
donors. Among total 741 reactive donors 587 donors were first time donors and 154 donors were
repeat donors. Out of total 360 (48.9%) replacement reactive samples 222(61.6%) samples were
sero positive NAT positive, 112(31.1%) and 26(7.2%) were reactive only by NAT. among
381(51.1%) voluntary reactive samples,206(54%) were reactive on both serology and IDNAT,
239(33.3%) samples have sero yield and 48(12.6%) were ID-NAT yield samples.
Conclusion:It was detected that 74 donor sample which were reactive by ID-NAT only they were
non-reactive on serology. 222 patients were protected from above mentioned viral infections who
were going to receive blood and blood components donated by these 74 NAT reactive donors which
were missed by serology assay because of window period.
- Article View: 82
- PDF Download: 103